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Clinical Study
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab
in patients with advanced cancers
Shiraj Sen1, Shumei Kato2, Rishi Agarwal3, Sarina Piha-Paul3, Kenneth Hess4, Daniel Karp3, Filip Janku3, Siqing Fu3, Aung Naing3,
Shubham Pant3, Gerald Falchook5, Chad Tang3, Xifeng Wu6, Yuanqing Ye6, Apostolia Tsimberidou3, Vivek Subbiah3, Razelle Kurzrock3,
Lauren Byers7, Shannon Westin8, JoAnn Lim3, Stacie Bean3, Allison Bass3, Ly Nguyen3, Funda Meric-Bernstam3 and David Hong3
BACKGROUND: We performed a phase I modified 3+ 3 dose escalation study to evaluate the safety and activity of bevacizumab
plus gemcitabine and nab-paclitaxel in patients with advanced solid tumours.
METHODS: Patients were given fixed dose gemcitabine plus increasing doses of nab-paclitaxel and bevacizumab. Toxicity,
response, and association with VEGF polymorphism was analysed.
RESULTS: The study enrolled 110 patients who had undergone a median of 3 prior lines of therapy. The median age was 60 years
(range, 17–85 years), and 55 patients (50%) had gemcitabine-refractory disease. We observed 3 dose-limiting toxicities during dose
escalation and 3 DLTs in expansion cohorts. Dose escalation to 150 mg/m2 nab-paclitaxel and 15mg/kg bevacizumab with 1000
mg/m2 of gemcitabine was well tolerated with no MTD. One patient with gemcitabine-refractory peritoneal papillary carcinoma had
a complete response, 13 patients (13%) had partial responses, and 54 patients (52%) had stable disease ≥12 weeks. Exploratory
VEGF single nucleotide polymorphism (SNP) analysis was performed on 13 patients.
CONCLUSIONS: The combination of gemcitabine, nab-paclitaxel, and bevacizumab is safe, well-tolerated, and has activity in
advanced malignancies, including gemcitabine-refractory tumours. Based on this study, the recommended phase 2 dose is
gemcitabine 1000mg/m2, nab-paclitaxel 125 mg/m2, and bevacizumab 15mg/kg. VEGF polymorphism data should be evaluated in
future bevacizumab-based trials.
British Journal of Cancer (2018) 118:1419–1424; https://doi.org/10.1038/s41416-018-0068-z
INTRODUCTION
Paclitaxel, an anti-microtubule agent approved by the U.S. Food
and Drug Administration (FDA), has demonstrated significant
activity alone and in combination with other chemotherapeutic or
biologic agents in ovarian, breast, and lung cancer and AIDS-
related Kaposi sarcoma.1 Unfortunately, owing to its hydrophobic
nature, paclitaxel must be formulated in a castor oil-derived
solvent, which leads to paclitaxel-associated hypersensitivity
reactions and myelosuppression that often limit its administration,
especially in heavily pretreated patients. Nanoparticle albumin-
bound paclitaxel (nab-paclitaxel), a solvent-free formulation of
paclitaxel, was developed to reduce such toxicity and decrease
infusion time through improved drug delivery.2 The U.S. FDA has
approved nab-paclitaxel as a single agent for the treatment of
metastatic breast cancer3 and the combination of nab-paclitaxel
plus gemcitabine for the treatment of pancreatic cancer.4
In preclinical studies, nab-paclitaxel has demonstrated anti-
tumour activity as a single agent and synergistic activity when
administered with gemcitabine. Specifically, the addition of nab-
paclitaxel increases intratumoural concentrations of gemcitabine.5
In a large phase III trial comparing the combination of nab-
paclitaxel and gemcitabine with single-agent gemcitabine in
patients with metastatic pancreatic cancer, the combination
improved the overall response rate from 7% to 22%, improved
the progression-free survival (PFS) duration from 3.7 months to
5.5 months, and improved the overall survival duration from
6.7 months to 8.5 months.4 The combination of nab-paclitaxel plus
gemcitabine has also demonstrated anti-tumour activity and a
favorable toxicity profile in early-phase trials in patients with
metastatic breast cancer6 and thoracic malignancies.7
Researchers have proposed several strategies to improve the
delivery of nab-paclitaxel plus gemcitabine to tumours. One such
strategy involves using anti-angiogenic therapy to target the
abnormal tumour vasculature that often prevents drug penetra-
tion. It has been suggested that the blockade of vascular
endothelial growth factor (VEGF), which stimulates tumour
angiogenesis, may improve the delivery of these drugs by
inducing morphologic normalisation of the tumour vasculature,
improve vessel stability, and reduce protein extravasation and
intra-tumoural pressure.8 Therefore, to determine whether the
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addition of VEGF inhibition improves the anti-cancer effects of
nab-paclitaxel plus gemcitabine, we performed a phase I dose-
escalation trial of the combination of bevacizumab, a monoclonal
antibody that inhibits VEGF-A, plus nab-paclitaxel and gemcita-
bine in patients with advanced cancers. We also assessed the
extent to which VEGF polymorphism is associated with survival.
METHODS
Patients
This study (NCT01113476) was performed at The University of
Texas MD Anderson Cancer Center under a protocol approved by
MD Anderson’s Institutional Review Board (protocol number
2009–0855). All participants provided written informed consent
before entering the study. We enrolled patients with histologically
confirmed metastatic or locally advanced solid tumours who were
seen at the Clinical Center for Targeted Therapy at MD Anderson
between May 2010 and July 2017. Eligible patients had disease
that had progressed despite standard therapy or for whom no
available therapy would likely increase survival by at least
3 months. Patients were required to be off systemic therapy for
at least 4 weeks (or for the time of 5 half-lives, in the case of
biologic or targeted agents). Other inclusion criteria included an
Eastern Cooperative Oncology Group performance status of 0–2,
absolute neutrophil count ≥1000/µl, platelet count ≥50,000/µl,
total bilirubin level ≤3mg/dl, alanine aminotransferase level <5
times the institutional upper limit of normal, creatinine level <3
times the institutional upper limit of normal, and the use of
contraception during the study. Patients were excluded if they
had a history of myocardial infarction within 6 months prior to
starting the treatment, were pregnant or breastfeeding, had
uncontrolled hypertension (systolic blood pressure >140mmHg or
diastolic blood pressure >90mmHg on medication), had any
unhealed wounds, and/or had undergone a major surgical
procedure and/or had clinically significant, unexplained bleeding
within 28 days prior to starting the treatment. Patients with any
prior hypersensitivity reaction to bevacizumab, gemcitabine,
paclitaxel, and/or nab-paclitaxel were also excluded. Patients
were allowed to receive palliative radiation therapy but not
allowed to use other standard or investigational anti-cancer
agents during the study period.
Study design and treatment
This study was a non-randomised, open-label, modified 3+ 3 dose
escalation study of gemcitabine at a fixed dose of 1000mg/m2
(days 1, 8, and 15), nab-paclitaxel at doses of 50–150 mg/m2 (days
1, 8, and 15), and bevacizumab at doses of 5–15mg/kg (days 1
and 15). The dose escalation design is illustrated in Table 1. The
primary objective was to determine the safety, maximum
tolerated dose (MTD), and dose limiting toxicities (DLTs) of the
drug combination. The secondary objective was to describe the
anti-tumour efficacy of the drug combination. Because nab-
paclitaxel and bevacizumab were given sequentially in escalating
doses, we investigated a variety of dose levels using a modified 3
+ 3 study design,9 which enabled us to determine multiple
potential MTDs of each drug given in combination.
An MTD was defined as the dose level below the dose level at
which 2 of 6 patients experienced drug-related DLTs in the first
cycle. DLTs were any grade 3 or 4 non-haematologic toxicity
(except nausea and vomiting responsive to supportive therapy),
any grade 4 haematologic toxicity lasting 2 weeks or longer
despite supportive care, unless complicated by fever or infection,
bleeding symptomatic anaemia, or other symptoms concerning to
the treating physician, and grade 4 nausea or vomiting
lasting more than 5 days despite maximum therapy. The
escalation path was determined by the DLTs that patients at
prior dose levels experienced. If 2 patients experienced DLTs at a
dose level and the DLTs could both be attributed to either nab-
paclitaxel or bevacizumab, all future dose levels with that dose of
the drug would be deemed inadmissible. If each of the two DLTs
could be attributed to a different drug, 6 additional patients would
be enrolled to determine whether the dose level was the one
above the MTD. This schema was utilised to allow for the
possibility of more than 1 MTD, as may be expected when two
drugs at different, escalating dose levels are being investigated. If
patients with a particular tumour histology type had a response,
the study allowed for an expansion cohort to include a total of 14
patients with that tumour type, who would be treated at the
Table 1. Dose escalation schedule, number of patients treated, and DLTs
Dose
level
Nab-paclitaxel dose,
mg/m2, days 1, 8, 15
Bevacizumab dose,
mg/kg, days 1, 15
Gemcitabine dose,
mg/m2, days 1, 8, 15
Number of
patients treated
Number of patients with DLTsa
1 50 5 1000 3 0
2 75 5 1000 6 0
3 50 10 1000 6 1 (thrombocytopenia, dehydration,
dysphagia, and dyspnea)
4 100 5 1000 17 2 (1 diarrhoea; 1 fatigue)b
5 75 10 1000 16 1 (cellulitis); 2 (GI bleeding)b
6 50 15 1000 6 0
7 125 5 1000 7 0
8 100 10 1000 6 0
9 75 15 1000 18 0
10 150 5 1000 6 1 (bacteremia, fatigue, and
dehydration)
11 125 10 1000 3 0
12 100 15 1000 3 0
13 150 10 1000 3 0
14 125 15 1000 3 0
15 150 15 1000 3 0
Dosing scheme for patients who received the combination of nab-paclitaxel, gemcitabine, and bevacizumab in a 28-day cycle, as well as number of patients
treated at each dose level, and number of patients with DLTs at each dose level. IV intravenous. aAll DLTs were grade 3. bObserved in an expansion cohort
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highest current dose level. All such patients would be included in
the DLT analysis.
If a patient experienced new grade 3 or higher toxicity,
treatment was held until the condition was addressed and
recovered to grade 1 or baseline. The treating physicians were
then allowed to reduce the dose by up to 50% if the toxicity was
attributed to nab-paclitaxel and/or bevacizumab. The patients
continued the treatment until they had disease progression or
intolerable toxicities; until the treating physicians or patients
believed that it was not in the patients’ best interest to continue
treatment for any reason; or until patients withdrew consent for
any reason.
All patients were evaluated for DLTs during the first 28 days. The
patients were evaluated in the clinic every 28 days prior to
initiation of each subsequent cycle. Response to therapy was
assessed every 2 cycles using Response Evaluation Criteria in Solid
Tumours (RECIST) version 1.1.10
VEGF polymorphism analysis
Thirteen patients agreed to have an optional blood draw for VEGF
polymorphism analysis. DNA samples were extracted from the
blood and genotyping was performed using the custom Infinium
Oncoarray Beadchip following the standard Illumina protocol. We
identified eight single nucleotide polymorphisms (SNPs) within 10
kb of the VEGF gene. We used the Fisher exact test to analyse the
association of these SNPs with treatment response and used the
log-rank test to analyse the association of these SNPs with PFS.
RESULTS
Patient characteristics
The characteristics of the 110 patients (48 men and 62 women)
who received at least 1 dose of nab-paclitaxel, gemcitabine, and
bevacizumab are shown in Table 2. The most common tumour
types enrolled were ovarian (n= 21), pancreatic (n= 19), sarcoma
(n= 10), urothelial (n= 7), gastroesophageal junction (n= 7),
gastric (n= 5), and small cell lung cancer (n= 4). The patients’
median age was 60 years (range, 17–85 years). The patients were
heavily pretreated with a median of 3 prior lines of therapy; 32
patients (29%) had received 3 prior lines of therapy, 29 (26%) had
received 4 prior lines of therapy, and 15 (13%) had received 5 or
more prior lines of therapy. Overall, 55 patients (50%) had
previously progressed on gemcitabine used either as a single
agent or in combination with other anti-cancer agents.
Of the 110 patients who received at least 1 dose of study drug,
4 did not complete the first treatment cycle, were replaced from
the study and deemed not evaluable for toxicity or response. (Of
these patients, 2 elected to go to hospice after receiving 1 dose of
the study drug, and the other 2 received 1 dose of the drug and
were admitted to the hospital for failure to thrive secondary to
advanced cancer.) Of the remaining 106 patients, 12 were
evaluable for toxicity but not response, as they withdrew consent
(n= 5), died prior to first restaging (n= 4), or were on dose level
15 and had not yet completed first restaging (n= 3). The
remaining 94 patients were evaluable for response.
Safety
Among the 106 patients evaluable for toxicity, three DLTs were
observed during dose escalation: one at dose level 3 with nab-
paclitaxel 50 mg/m2 and bevacizumab 10mg/kg (grade 3
thrombocytopenia, dehydration, dysphagia, and dyspnea); one
at dose level 5 with nab-paclitaxel 75 mg/m2 and bevacizumab 10
mg/kg (grade 3 cellulitis); and one at dose level 10 with nab-
paclitaxel 150 mg/m2 and bevacizumab 5mg/kg (grade 3
bacteremia, fatigue, and dehydration). Two DLTs (one grade 3
diarrhoea and one grade 3 fatigue) were observed among the 14
patients in the dose level 4 expansion cohort (14%) receiving nab-
paclitaxel 100 mg/m2 and bevacizumab 5mg/kg. Two DLTs (both
Table 2. Baseline demographics
Characteristic No. of patients (%)
Sex
Female 62 (55)
Male 48 (45)
Median age at study enrollment (range), years 60 (17–85)
Disease type
Ovarian cancer 21 (19)
Pancreatic cancer 19 (17)
Sarcoma 10 (9)
Urothelial cancer 7 (6)
Gastroesophageal junction cancer 7 (6)
Gastric cancer 5 (5)
Small cell lung cancer 4 (4)
Other 36 (34)
Median no. of prior lines of therapy (range) 3 (0–9)
≤2 34 (31)
3 32 (29)
4 29 (26)
≥5 15 (13)
Prior gemcitabine 55 (50)
Prior bevacizumab 27 (25)
Baseline demographics of all 110 patients treated on phase 1 trial with
nab-paclitaxel, gemcitabine, and bevacizumab. Sex, age, disease type,
number of lines of therapy, and number of patients with prior gemcitabine
and prior bevacizumab use are all listed. Note: All data are no. of patients
(%) unless otherwise indicated
Table 3. All grade 3 and 4 toxicities
Toxicity Grade No. of patients (%)
Neutropenia 3 19 (18)
4 7 (6)
Fatigue 3 8 (7)
Thrombocytopenia 4 3 (3)
3 6 (5)
Infection 3 7 (6)
Nausea 3 6 (5)
Diarrhoea 3 2 (2)
Lymphedema 3 1 (1)
Dysphagia 3 1 (1)
Dyspnea 3 2 (2)
GI bleed 3 3 (3)
2 1 (1)
Anaemia 3 4 (4)
Fever 3 3 (3)
2 1 (1)
Hypotension 3 2 (2)
Abdominal pain 3 2 (2)
2 1 (1)
Dysphagia 3 2 (2)
All grade 3 and 4 toxicities as well as number of patients experiencing each
toxicity while being treated with nab-paclitaxel, gemcitabine, and
bevacizumab. GI gastrointestinal
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grade 3 gastrointestinal bleeding) were observed among the 13
patients in the dose level 5 expansion cohort (15%) with nab-
paclitaxel 75 mg/m2 and bevacizumab 10mg/kg (Table 1). Dose
escalation up to nab-paclitaxel 150 mg/m2 and bevacizumab 15
mg/kg was well tolerated, with no MTD achieved.
All grade 3 and 4 toxicities experienced during dose escalation
and dose expansion are listed in Table 3. The most common grade
3 toxicity was neutropenia, which occurred in 19 patients (18%),
followed by fatigue in 8 patients (8%), infection in 7 patients (7%),
thrombocytopenia in 6 patients (6%), and nausea in 6 patients
(6%). Grade 4 haematologic toxicities included neutropenia in 7
patients (7%) and thrombocytopenia in 3 patients (3%). No grade
4 non-haematologic toxicities were observed. Sixty-two patients
(58%) required at least 1 dose of a drug to be held, and 29 patients
(27%) required dose reductions. Owing to toxicity, 22 patients
(21%) required gemcitabine dose reductions, 20 patients (19%)
required nab-paclitaxel dose reductions, and 4 patients (4%)
required bevacizumab dose reductions.
Response
Of the 106 patients who completed the first treatment cycle, 12
were not evaluable for response. Of these 12 patients, 5 were on
the protocol through the first cycle (DLT window) and were
evaluable for toxicity but withdrew consent prior to the first
restaging; 4 completed the first cycle but died prior to the first
restaging (1 from septic shock, 1 from pneumonia, and 2 from
unknown etiologies); and 3 had yet to complete restaging. The
deaths were not considered to be due to the study drugs. Of the
remaining 94 patients who underwent restaging and were
evaluable for response, 50 (53%) had objective tumour volume
reduction as best response. Overall, 1 patient with metastatic
primary peritoneal papillary carcinoma treated on dose level 5
with nab-paclitaxel 50 mg/m2 and bevacizumab 10mg/kg had a
complete response. This patient’s disease had been refractory to
gemcitabine plus carboplatin as well as a docetaxel plus
bevacizumab. Of the 14 patients (14%) who had a partial response
(PR), 6 had disease that had been refractory to gemcitabine-based
therapy.
The treatment responses of the 94 patients evaluable for
response are shown in Fig. 1. Fourteen patients (15%)—1 with
ampulla of vater adenocarcinoma, 1 with GE junction adenocarci-
noma, 1 with pancreatic adenocarcinoma, 2 with squamous cell
carcinoma of the oesophagus, 2 with B cell lymphoma, 4 with
ovarian adenocarcinoma, 2 with small cell lung cancer, and 1 with
small cell carcinoma of the bladder—had PRs. Among these 14
patients who achieved a PR, 1 of the 2 patients with B cell
lymphoma, 3 of the 4 patients with ovarian adenocarcinoma, and
the 1 patient with pancreatic adenocarcinoma had gemcitabine-
refractory disease. Twenty-five patients (27%) had disease progres-
sion at first restaging. Two patients with leiomyosarcoma and 1
patient with ovarian adenocarcinoma remain on protocol with
continued clinical response after 5, 7, and 7 months, respectively.
Notable responses were seen in 4 subsets of patients—
gastroesophageal cancers, pancreatic cancer, small cell cancers,
and ovarian cancer. Of the 17 patients with gastroesophageal
cancers, 3 had PRs, 10 had stable disease (SD), and 4 had disease
progression as best response. Both the patients with squamous
cell carcinoma of the oesophagus had PRs with 44% and 47%
tumour shrinkage, respectively, as best response. Of the 15
patients with pancreatic cancer, 1 had a PR with 57% tumour
shrinkage, 10 (67%) had SD (9 of these patients had tumour
shrinkage as best response), and 4 (27%) had disease progression
before or at first restaging. Among the 6 patients with small cell
cancers—4 with small cell lung cancer, 1 with small cell prostate
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No prior gemcitabine treatment80%
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Fig. 1 Waterfall plot depicting best response as a percent change in target lesion size in all evaluable patients. Patients previously treated with
gemcitabine are indicated with blue
Baseline
a
Cycle 3 day 1
b Baseline
S 17
Cycle 3 day 1
Fig. 2 Notable responses to gemcitabine, nab-paclitaxel, and bevacizumab. Representative restaging images of two patients who had notable
responses to therapy. a A patient with small cell lung cancer treated on dose level 9 who had a partial response after disease progression on
first-line carboplatin plus etoposide and second-line topotecan. b A patient with B-cell lymphoma treated on dose level 5 who had a partial
response after disease progression on R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), DHAP (rituximab,
cisplatin, cytarabine, and dexamethasone), BR (bendamustine and rituximab), and an experimental interleukin-1 antagonist
Phase I study of nab-paclitaxel, gemcitabine, and bevaci...
S Sen et al.
1422
cancer, and 1 with small cell bladder cancer—only 1 of the small
cell lung cancer patient had disease progression as best response,
and the other 5 patients had tumour shrinkage of at least 25% as
best response. Finally, of the 17 patients with ovarian cancer and
measurable disease, 4 (24%) had PR as best response, 9 patients
(53%) had SD as best response, and 4 patients (24%) had
progressive disease (PD) as best response. Two additional ovarian
cancer patients who had no measurable disease at the time of trial
enrollment had SD for more than 6 months before having disease
progression. Of the 19 evaluable patients with ovarian cancer, 8
(44%) had serous carcinomas, and each of these patients had
tumour shrinkage of at least 20% as best response, representing 4
PRs and 4 SDs. Of the 8 patients with tumour shrinkage, 6 (75%)
previously had gemcitabine-refractory disease. Representative
images of patients with notable responses are shown in Fig. 2.
VEGF polymorphism analysis
Response rates and PFS duration of the 13 patients that agreed to
optional VEGF polymorphism data collection were analysed. Eight
of the nine VEGF SNPs analysed demonstrated no statistical
association between SNP genotype and PFS. The PFS duration of
the 2 patients with the GA genotype in the rs6900017 VEGF SNP
(84 days, 95% CI= 84–not reached) was significantly shorter than
that of the 11 patients with the GG genotype in the SNP (308 days,
95% CI= 91–392, p= 0.02).
DISCUSSION
Gemcitabine remains a backbone for the treatment of pancreatic,
ovarian, lung, and breast cancer. The addition of nab-paclitaxel to
gemcitabine is well tolerated in thoracic and breast malignancies7,
11 and improves PFS and overall survival in pancreatic cancer.4 The
MTD of gemcitabine and nab-paclitaxel in advanced pancreatic
cancer was previously found to be gemcitabine 1000mg/m2 and
nab-paclitaxel 125 mg/m2.12 The results of this phase I trial identify
that the addition of bevacizumab to gemcitabine and nab-
paclitaxel is safe, well tolerated, and has clinical activity in patients
with advanced cancers. The MTD was not reached, and dose
escalation to the highest prespecified doses of gemcitabine (1000
mg/m2), nab-paclitaxel (150 mg/m2), and bevacizumab (15 mg/kg)
was achieved.
In order to promote generalisability of our results and include
representative patients with advanced cancer on this trial, broad
eligibility criteria were applied and allowed all patients with
platelet counts greater than 50 × 103/µl, bilirubin levels less than
3.0 mg/dl, and creatinine levels less than 3 times the upper limit of
normal. Many of these patients have traditionally been excluded
from gemcitabine-based trials and further analysis is ongoing to
evaluate whether broadening certain eligibility criteria may have
contributed to the presence of toxicities in a non-dose dependent
fashion in this and in other trials. In the present study, DLTs
included grade 3 sepsis, bleeding, fatigue, and diarrhoea.
Toxicities were neither dose dependent nor associated with prior
gemcitabine use, prior nab-paclitaxel use, age, or performance
status. Sepsis was not an unexpected DLT as it was also seen in
early-phase studies combining gemcitabine and nab-paclitaxel.12
The incidences of grade 3 fatigue and diarrhoea and grade 2
peripheral neuropathy—non-haematologic toxicities known to
occur in select patients treated with gemcitabine and nab-
paclitaxel12—were lower in this trial than in previous studies, likely
owing to improvements in supportive care over the last decade.
Interestingly, of the 14 patients who had grade 1 or 2 peripheral
neuropathy, 13 experienced tumour shrinkage. In the randomised
phase III MPACT trial, a subset analysis demonstrated an
association between peripheral neuropathy and survival in
patients with metastatic pancreatic adenocarcinoma treated with
gemcitabine and nab-paclitaxel.13 Our data suggest a similar
association in non–pancreatic cancer patients treated with this
combination of drugs. Moreover, our data highlight the impor-
tance of recognising and optimally managing peripheral neuro-
pathy through dose reduction and pharmacologic intervention to
enable patients to continue therapy and potentially derive benefit
from it.
At dose level 5 (10 mg/kg bevacizumab), 2 patients had DLTs in
the form of grade 3 bleeding. One of these patients had recently
started therapeutic doses of enoxaparin sodium for a venous
thromboembolism and had grade 1 thrombocytopenia, which
likely triggered bleeding from his small bowel adenocarcinoma on
cycle 1 day 14. The second patient, who had metastatic pancreatic
cancer that was refractory to gemcitabine plus cisplatin as well as
capecitabine plus irinotecan, had been on the trial for 5 months
with a sustained PR (57% tumour shrinkage from baseline). This
patient had recently undergone aortic valvuloplasty for severe
aortic stenosis and was taking aspirin and clopidogrel, which likely
increased the risk for bleeding. These findings underscore the
need to constantly monitor patients treated with bevacizumab for
gastrointestinal hemorrhage risk, especially those concurrently
receiving anti-platelet and/or anti-coagulation therapy. It has been
hypothesised in preclinical studies that the enhanced hemor-
rhagic toxicity from this combination is a result of nab-paclitaxel
upregulation of VEGF-A production, but the combination could
elicit complete responses despite the absence of such responses
with either agent alone.14
Our trial also demonstrates that the combination of gemcita-
bine, nab-paclitaxel, and bevacizumab has activity even in
previously gemcitabine-refractory cancers. The overall response
rate of the 94 patients who were evaluated for response was 16%.
In particular, 1 patient whose metastatic peritoneal papillary
carcinoma had been refractory to gemcitabine and to docetaxel
plus bevacizumab had a complete response. In the present study,
patients with pancreatic cancer, gastroesophageal cancer, small
cell cancer, and ovarian cancer had clinical responses to the
combination therapy. Further data to support the combination of
nab-paclitaxel, bevacizumab, and gemcitabine has previously
been published in a case report that noted a 3-year complete
remission in a patient with metastatic triple-negative breast
cancer.15 Similarly, the combination of hepatic arterial infusion of
nab-paclitaxel plus systemic gemcitabine and bevacizumab has
had activity in patients with advanced cancers and liver
metastases.16
Bevacizumab has been added to other gemcitabine-based
combination therapies for pancreatic cancer but has not improved
survival.17, 18 However, given the favorable safety profile
associated with the addition of bevacizumab to gemcitabine
and nab-paclitaxel in the present trial, further investigation of this
combination in a phase 2 study in patients with gastroesophageal,
ovarian, or small cell cancers is being considered. Paclitaxel-based
regimens are already approved by the U.S. FDA for use in
gastroesophageal cancers,19 and nab-paclitaxel has been found to
be non-inferior to paclitaxel in patients with advanced gastric
cancer.20 Moreover, early-phase trial data suggest that the
addition of front-line bevacizumab is well tolerated and improves
outcomes in patients with advanced gastroesophageal adenocar-
cinomas.21 Similarly, bevacizumab and paclitaxel are approved by
the FDA for platinum-sensitive ovarian cancers,22 and nab-
paclitaxel–based regimens have demonstrated activity against
small cell lung cancer.23 Such data underscore the need to identify
a biomarker to predict response to this regimen in order to
determine whether it may be clinically relevant to consider in
these cancers.
A previous study suggests that VEGF polymorphisms predict
response to bevacizumab treatment.24 In the present study,
polymorphisms in the rs6900017 VEGF SNP were associated with
statistically significant differences in PFS. The PFS duration of
patients with the GA genotype was significantly shorter than that
of patients with the GG genotype. However, the optional,
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exploratory analysis included only 13 patients, and further
investigation of the association of response to bevacizumab-
based regimens and VEGF is warranted in order to determine
efficacy. Others have hypothesised that polymorphisms in IL8,
eNOS,25 and autophagy-related genes26 predict bevacizumab-
based therapy response and toxicity, further suggesting that
genomic signatures may be used to help oncologists individualise
cancer therapy.
As is the case with all non-randomised phase I trials, patient
selection in the present study may have affected the outcomes.
Further investigation of the combination of gemcitabine, nab-
paclitaxel, and bevacizumab in patients with gastroesophageal,
small cell, and ovarian cancers is warranted. The combination of
gemcitabine and nab-paclitaxel is one of the options for treatment
of patients with advanced pancreatic cancer. This study demon-
strates that the combination of gemcitabine, nab-paclitaxel, and
bevacizumab can shrink even gemcitabine-refractory pancreatic
tumours. Further studies to identify biomarkers that predict
response to bevacizumab-based therapy are needed.
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